Red Spruce Capital’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.96M | Hold |
15,577
| – | – | 0.85% | 39 |
|
|
2025
Q1 | $1.72M | Sell |
15,577
-344
| -2% | -$38K | 0.81% | 46 |
|
|
2024
Q4 | $2.17M | Buy |
15,921
+15
| +0.1% | +$2.05K | 0.96% | 35 |
|
|
2024
Q3 | $1.83M | Sell |
15,906
-244
| -2% | -$28.1K | 0.83% | 44 |
|
|
2024
Q2 | $2.22M | Buy |
16,150
+124
| +0.8% | +$17.1K | 1.03% | 33 |
|
|
2024
Q1 | $2.21M | Hold |
16,026
| – | – | 1.03% | 33 |
|
|
2023
Q4 | $2.11M | Buy |
16,026
+101
| +0.6% | +$13.3K | 1.08% | 32 |
|
|
2023
Q3 | $1.79M | Hold |
15,925
| – | – | 1.02% | 36 |
|
|
2023
Q2 | $1.5M | Buy |
15,925
+261
| +2% | +$24.6K | 0.81% | 48 |
|
|
2023
Q1 | $1.59M | Buy |
15,664
+386
| +3% | +$39.1K | 0.93% | 41 |
|
|
2022
Q4 | $1.82M | Buy |
15,278
+75
| +0.5% | +$8.96K | 1.16% | 30 |
|
|
2022
Q3 | $1.62M | Buy |
15,203
+121
| +0.8% | +$12.9K | 1.13% | 32 |
|
|
2022
Q2 | $1.47M | Buy |
15,082
+228
| +2% | +$22.2K | 0.98% | 35 |
|
|
2022
Q1 | $1.39M | Buy |
14,854
+1,915
| +15% | +$180K | 0.79% | 48 |
|
|
2021
Q4 | $1.1M | Buy |
12,939
+1,193
| +10% | +$102K | 0.6% | 57 |
|
|
2021
Q3 | $1.13M | Sell |
11,746
-105
| -0.9% | -$10.1K | 0.66% | 56 |
|
|
2021
Q2 | $1.15M | Hold |
11,851
| – | – | 0.68% | 55 |
|
|
2021
Q1 | $1.15M | Buy |
11,851
+285
| +2% | +$27.7K | 0.73% | 50 |
|
|
2020
Q4 | $1.11M | Buy |
11,566
+422
| +4% | +$40.5K | 0.77% | 48 |
|
|
2020
Q3 | $1.07M | Buy |
11,144
+1,235
| +12% | +$119K | 0.87% | 44 |
|
|
2020
Q2 | $1.21M | Buy |
9,909
+36
| +0.4% | +$4.39K | 1.03% | 37 |
|
|
2020
Q1 | $855K | Sell |
9,873
-53
| -0.5% | -$4.59K | 0.89% | 44 |
|
|
2019
Q4 | $1.07M | Buy |
+9,926
| New | +$1.07M | 0.89% | 52 |
|